American Regent v. Sun Pharma: Selenious Acid Patent Case Consolidated in 21 Days
American Regent, Inc. filed suit against Sun Pharmaceutical Industries, Inc. in the New Jersey District Court, asserting US12150957B2 over competing selenious acid injection products. The case was consolidated within 21 days into the broader In re Selenious Acid Litigation alongside 12 parallel actions against generic pharma defendants.
Multi-front ANDA battle over selenious acid drives rapid consolidation
On December 13, 2024, American Regent, Inc. filed Civil Action No. 2:24-cv-11126 in the New Jersey District Court against Sun Pharmaceutical Industries, Inc. and Sun Pharmaceutical Industries Limited, asserting infringement of US12150957B2. The patent covers ARI’s selenious acid injection product — 600 mcg/10 mL (60 mcg/mL selenium) — a parenteral micronutrient used in intravenous nutrition. Sun’s accused product is its Selenious Acid Injection, USP, 600 mcg/10 mL, a generic equivalent.
The case terminated on January 3, 2025 — just 21 days after filing — not through a merits ruling but through consolidation. The Court ordered this action merged into the pre-existing consolidated matter In re Selenious Acid Litigation, Civil Action No. 2:24-cv-7791, which had already been pending. All future filings, including Sun Pharma’s responsive pleadings, will proceed under that consolidated caption before Judge Brian R. Martinotti.
The speed of consolidation is consistent with a coordinated Hatch-Waxman ANDA enforcement campaign, where a brand holder triggers the 30-month stay by filing against multiple generic filers simultaneously. ARI filed 12 parallel actions on the same day against defendants including Accord, Cipla, Dr. Reddy’s, Hikma, Zydus, and others — suggesting simultaneous ANDA paragraph IV certifications. The substantive validity and infringement questions remain entirely open in the consolidated docket.
Filing to Case Consolidated in 21 days
21 days — exceptionally fast resolution; consolidation typically signals coordinated multi-defendant ANDA strategy
Case consolidated: what the transfer into In re Selenious Acid Litigation means
Consolidation is a procedural merge, not a merits ruling
When a court consolidates related actions under Fed. R. Civ. P. 42(a), it does not dismiss or adjudicate any claim. All rights, defenses, and allegations from Case No. 2:24-cv-11126 survive and are absorbed into the lead case (2:24-cv-7791). Sun Pharma remains a defendant; ARI’s infringement claims remain live. The case simply proceeds more efficiently under a single docket.
No merits determinationSame court, same judges — administrative efficiency only
Consolidation here does not involve a change of venue — all actions remain before the New Jersey District Court with Judge Martinotti. The practical effect is that discovery, claim construction, and trial schedules will be unified across all 13 defendant groups. Sun Pharma’s litigation obligations are now governed by the consolidated scheduling order rather than any standalone case management plan.
NJ District Court retainedSubstantive litigation continues in the consolidated docket
Sun Pharma must still answer or otherwise respond to ARI’s complaint within the consolidated proceeding. Key upcoming milestones in the lead case will include invalidity contentions, claim construction briefing (Markman), and potentially summary judgment. The 30-month Hatch-Waxman stay — if triggered by timely filing — may prevent Sun’s generic from launching during this period, giving the consolidated litigation significant commercial stakes.
Active in 2:24-cv-779113-defendant consolidation amplifies the pressure on US12150957B2
With 12+ generic manufacturers now co-defendants, the validity of US12150957B2 will be tested from multiple angles simultaneously. A finding of invalidity by any defendant benefits all; a successful enforcement by ARI locks out the entire generic field. This structural dynamic typically incentivises early settlement by smaller ANDA filers while larger players like Sun and Dr. Reddy’s may carry the litigation to judgment.
High-stakes multi-party ANDAFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | American Regent, Inc. | Company | Pharmaceutical manufacturer and parenteral nutrition specialist — holder of US12150957B2Search in Eureka ↗ |
| Defendant | Sun Pharmaceutical Industries, Inc. | Company | Major Indian generic pharmaceutical group seeking U.S. market entry for selenious acid injectionSearch in Eureka ↗ |
| Plaintiff counsel | Charles H. Chevalier | Attorney | Counsel for American Regent, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Christine A. Gaddis | Attorney | Counsel for American Regent, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Gibbons PC | Law Firm | Representing American Regent, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The consolidation order reflects the Court’s recognition that all 13 actions share a common patent, overlapping claim construction issues, and a common plaintiff. The verdict text does not adjudicate infringement or validity — it is purely procedural. For Sun Pharma, consolidation means its defence strategy will be shaped by the collective briefing schedule and any co-defendants’ invalidity arguments. For ARI, the consolidated forum provides leverage: a single favourable claim construction ruling applies across all defendants simultaneously.
US12150957B2 — Selenious Acid Injection 600 mcg/10 mL Parenteral Formulation
US12150957B2, filed under application number US18/672876, protects ARI’s selenious acid injection product — a sterile parenteral formulation delivering 600 mcg of selenium per 10 mL (60 mcg/mL) for intravenous administration. Selenium is an essential trace element in parenteral nutrition protocols, particularly for critically ill and long-term TPN-dependent patients. The patent’s relatively recent application number suggests it may be a continuation of earlier selenium formulation IP, consistent with lifecycle management strategies common in branded parenteral nutrition.
For competitors seeking FDA approval of a generic selenious acid injection via the ANDA pathway, US12150957B2 represents the primary regulatory and legal barrier. ARI’s enforcement of this patent against 12 concurrent generic filers signals that the formulation claims are considered broadly defensive. Any company active in the parenteral micronutrient space — particularly those with selenium injection ANDAs pending or approved — should treat this patent as a core FTO concern. The outcome of the consolidated litigation will define the competitive landscape for this product category for the next several years.
Should you run an FTO analysis against US12150957B2?
Any pharmaceutical manufacturer, contract development organisation, or ANDA applicant working on selenious acid injection products — particularly formulations at or near 60 mcg/mL selenium — should conduct a freedom-to-operate analysis against US12150957B2 before advancing to NDA or ANDA submission. The breadth of ARI’s enforcement campaign (12 defendants, simultaneous filing) strongly suggests the patent’s claims are drafted to capture the standard commercial concentration range for this product category.
PatSnap Eureka’s FTO Search Agent enables IP and R&D teams to map claim scope against proposed formulation parameters, identify prior art that may support design-around strategies, and monitor the In re Selenious Acid Litigation docket for claim construction rulings that narrow or broaden enforceability. Set automated alerts on US12150957B2 to track any continuation filings, IPR petitions, or litigation updates that affect your product pipeline.
Run a freedom-to-operate analysis on US12150957B2 to assess your product’s exposure
Run FTO in Eureka →Similar Hatch-Waxman selenious acid and parenteral pharma patent cases
Browse related ANDA infringement actions over parenteral nutrition formulations in the New Jersey District Court and comparable multi-defendant pharma consolidations.
What this case signals for the parenteral nutrition IP landscape
ARI’s simultaneous 12-front filing is a textbook Hatch-Waxman enforcement strategy — and its outcomes will set pricing and market access terms for selenium supplementation.
Simultaneous ANDA filings trigger automatic 30-month stay protection
By filing all 12 actions on the same day — December 13, 2024 — ARI likely secured the Hatch-Waxman 30-month stay against each ANDA filer simultaneously. This prevents any defendant from launching a generic selenious acid product during the pendency of litigation, giving ARI market exclusivity through mid-2027 absent a court order shortening the stay.
Consolidation compresses defendant leverage but raises invalidity risk
Multi-defendant consolidation benefits plaintiffs through efficiency but concentrates patent validity challenges. With defendants including Cipla, Dr. Reddy’s, Hikma, and Sun all contesting the same patent, ARI faces coordinated invalidity arguments. A single successful prior art or obviousness argument can be adopted by all defendants — making the validity of US12150957B2 the central commercial question.
American v Sun — key questions answered
The case was terminated on January 3, 2025 through consolidation — not a merits ruling. The Court ordered Case No. 2:24-cv-11126 merged into the lead consolidated matter In re Selenious Acid Litigation (2:24-cv-7791). ARI’s infringement claims against Sun Pharma remain live and continue under the consolidated docket.
American Regent asserts US12150957B2 (application number US18/672876), covering its selenious acid injection formulation at 600 mcg/10 mL (60 mcg/mL selenium). Sun’s accused product is its Selenious Acid Injection, USP, 600 mcg/10 mL — a direct concentration equivalent to ARI’s branded product.
The consolidated action includes 13 civil actions filed on December 13, 2024, naming defendants including Accord Healthcare, Aspiro Pharma, Cipla, Dr. Reddy’s Laboratories, Gland Pharma, Hikma Pharmaceuticals USA, RK Pharma, Somerset Therapeutics/Odin Pharmaceuticals, Sun Pharmaceutical Industries, Xiromed, and Zydus Pharmaceuticals — all in addition to the pre-existing 2:24-cv-7791 action.
No. Consolidation under Fed. R. Civ. P. 42(a) is a procedural administrative order, not a dismissal. All claims, defences, and parties from Case No. 2:24-cv-11126 are absorbed into the consolidated docket. Sun Pharma remains a named defendant and must respond to ARI’s infringement allegations in the lead case 2:24-cv-7791.
Under the Hatch-Waxman Act, a brand drug holder that files an infringement suit within 45 days of receiving a Paragraph IV ANDA notice triggers an automatic 30-month stay preventing FDA final approval of the generic. ARI’s simultaneous December 13, 2024 filings against 12 defendants suggests coordinated receipt of Paragraph IV certifications, potentially staying all 12 generics through approximately mid-2027.
PatSnap Eureka searches patents and litigation data to answer instantly.